- Home
- JSPR vs ACHV Comparison
JSPR vs ACHV Comparison
Compare JSPR & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ACHV
- Stock Information
- Founded
- JSPR 2018
- ACHV N/A
- Country
- JSPR United States
- ACHV Canada
- Employees
- JSPR N/A
- ACHV N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- JSPR Health Care
- ACHV Health Care
- Exchange
- JSPR Nasdaq
- ACHV Nasdaq
- Market Cap
- JSPR 85.8M
- ACHV 72.5M
- IPO Year
- JSPR N/A
- ACHV N/A
- Fundamental
- Price
- JSPR $4.77
- ACHV $3.04
- Analyst Decision
- JSPR Strong Buy
- ACHV Strong Buy
- Analyst Count
- JSPR 11
- ACHV 3
- Target Price
- JSPR $62.22
- ACHV $14.33
- AVG Volume (30 Days)
- JSPR 152.4K
- ACHV 207.3K
- Earning Date
- JSPR 05-12-2025
- ACHV 05-13-2025
- Dividend Yield
- JSPR N/A
- ACHV N/A
- EPS Growth
- JSPR N/A
- ACHV N/A
- EPS
- JSPR N/A
- ACHV N/A
- Revenue
- JSPR N/A
- ACHV N/A
- Revenue This Year
- JSPR N/A
- ACHV N/A
- Revenue Next Year
- JSPR N/A
- ACHV N/A
- P/E Ratio
- JSPR N/A
- ACHV N/A
- Revenue Growth
- JSPR N/A
- ACHV N/A
- 52 Week Low
- JSPR $3.13
- ACHV $1.84
- 52 Week High
- JSPR $26.84
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- JSPR 49.05
- ACHV 59.33
- Support Level
- JSPR $4.57
- ACHV $2.96
- Resistance Level
- JSPR $5.20
- ACHV $3.32
- Average True Range (ATR)
- JSPR 0.37
- ACHV 0.23
- MACD
- JSPR -0.00
- ACHV 0.06
- Stochastic Oscillator
- JSPR 53.76
- ACHV 71.43
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.